The expression level of PD‐L1 in the tumor microenvironment (TME) and the tumor mutation burden (TMB) [8] could serve as vital indicators for predicting the response to ICIs in NSCLC patients without EGFR mutation. This evidence concerns the gene EGFR and neoplasm.